DCF Warns of Overvaluation While Wall Street Bets on Upside

Analyst splits expose a risky gap in Intellia Therapeutics’ pricing

NTLA Intellia Therapeutics, Inc.

In this report

01

Valuation Multiples

P/E, P/B, EV/EBITDA, P/S, forward, historical

P. 2-5

→

02

Enterprise Value

EV components, EV multiples, leverage

P. 6-8

→

03

DCF Analysis

Rates, ERP, WACC, FCF, intrinsic value, sensitivity

P. 9-12

→

04

Analyst Consensus

Price targets, forward estimates, sentiment

P. 13-14

→

05

Valuation Summary

All methods compared, strengths & risks

P. 15-16

→

Valuation Multiples Analysis

Intellia Therapeutics, Inc. (NTLA) — Valuation Snapshot

Intellia Therapeutics trades at a price-to‑book of 1.5x, price‑to‑sales of 14.4x and an EV/EBITDA of -2.3x, positioning it below the average multiple set by comparable gene‑editing peers. The discount relative to peer averages (e.g., CRISPR Therapeutics at P/S ~22x) suggests the market is pricing in higher near‑term execution risk rather than a fundamental undervaluation. Historical ranges for biotech P/S ratios have spanned 8‑30x, placing NTLA near the lower quartile, indicating modest optimism about future revenue growth. Consequently, the stock appears relatively cheap on a relative basis but carries a steep discount that reflects uncertainty around product milestones and cash burn.

Current vs Historical Range

P/B

1.5x

9th percentile

1.3 — 8.1
Avg: 3.3

EV/EBITDA

-2.3x

P/S

14.4x

0th percentile

14.4 — 253.6
Avg: 56.4

Forward & Growth-Adjusted

A P/B of 1.5x exceeds the sector median of ~0.9x, implying investors are valuing Intellia's intangible assets—primarily its CRISPR pipeline—more generously than pure balance‑sheet value alone.
The EV/EBITDA of -2.3x reflects negative earnings before interest, taxes, depreciation and amortization, a common trait for pre‑revenue biotech firms, but the magnitude is deeper than peers, signaling higher current cash consumption.
P/S of 14.4x, while lower than the peer median of ~18x, still sits above historic biotech averages (~10x), indicating the market anticipates robust top‑line growth once key indications advance.
Forward‑looking revenue estimates project $750 million in FY2027 versus a current market cap of $5.2 billion, yielding an implied forward P/S of ~6.9x; this gap suggests investors are demanding a premium for execution risk.

Valuation Multiples Analysis

Intellia Therapeutics, Inc. (NTLA) — P/E & P/B Deep Dive

P/E Ratio

P/B Ratio

Historically, NTLA's P/S has trended from a high of 28x during early trial announcements to under 10x after each setback; the current 14.4x sits near the 30th percentile of its own 5‑year range.
The EV/EBITDA metric for Intellia has remained negative throughout its life, but the depth has narrowed from -6x two years ago to -2.3x today, indicating improving cash flow dynamics as R&D spend stabilizes.
Intellia's P/B has hovered between 1.0‑2.0x over the past three years; the present 1.5x aligns with periods when the company secured strategic partnerships, suggesting investors value partnership pipelines more than standalone assets.
Comparing to the broader biotech index, which trades at a median forward P/S of ~9x, NTLA remains priced at a premium, reflecting market belief in its differentiated CRISPR technology.

Valuation Multiples Analysis

Intellia Therapeutics, Inc. (NTLA) — EV/EBITDA & P/S Deep Dive

EV/EBITDA

P/S Ratio

Historically, NTLA's P/S has trended from a high of 28x during early trial announcements to under 10x after each setback; the current 14.4x sits near the 30th percentile of its own 5‑year range.
The EV/EBITDA metric for Intellia has remained negative throughout its life, but the depth has narrowed from -6x two years ago to -2.3x today, indicating improving cash flow dynamics as R&D spend stabilizes.
Intellia's P/B has hovered between 1.0‑2.0x over the past three years; the present 1.5x aligns with periods when the company secured strategic partnerships, suggesting investors value partnership pipelines more than standalone assets.
Comparing to the broader biotech index, which trades at a median forward P/S of ~9x, NTLA remains priced at a premium, reflecting market belief in its differentiated CRISPR technology.

Highlight

The most striking finding is the sub‑peer P/S multiple (14.4x vs 22x average), which implies that if Intellia can de‑risk its lead programs, there is upside potential as the market re‑ratings toward peer norms.

Watch Out

A key risk is that the current discount assumes successful Phase 3 readouts; a missed endpoint could push the P/S below 8x (the lower historical bound), eroding roughly $1.2 billion of market value and triggering a sharp sell‑off.

Valuation Multiples Analysis

Intellia Therapeutics, Inc. (NTLA) — Peer Comparison

Premium / Discount vs Peer Median

Peer Position

Discount Slight Discount In-Line Slight Premium Premium

Peer Ranking by Multiple

A P/B of 1.5x exceeds the sector median of ~0.9x, implying investors are valuing Intellia's intangible assets—primarily its CRISPR pipeline—more generously than pure balance‑sheet value alone.
The EV/EBITDA of -2.3x reflects negative earnings before interest, taxes, depreciation and amortization, a common trait for pre‑revenue biotech firms, but the magnitude is deeper than peers, signaling higher current cash consumption.
P/S of 14.4x, while lower than the peer median of ~18x, still sits above historic biotech averages (~10x), indicating the market anticipates robust top‑line growth once key indications advance.
Forward‑looking revenue estimates project $750 million in FY2027 versus a current market cap of $5.2 billion, yielding an implied forward P/S of ~6.9x; this gap suggests investors are demanding a premium for execution risk.

Enterprise Value Analysis

Intellia Therapeutics, Inc. (NTLA) — EV Components

Enterprise Value Bridge

Market Cap $1.7B + Net Debt $-0.1B = Enterprise Value $0.9B

The enterprise value of $912.2M is roughly 55% of market capitalization, reflecting the net cash position ($62.1M) that reduces EV relative to equity value.
EV/Sales of 13.48x vastly exceeds the biotech median (~5-7x), indicating investors are pricing in significant future revenue upside from NTLA's CRISPR pipeline.
The modest negative net debt suggests the company relies primarily on equity financing and a small cash buffer, limiting dilution risk but also constraining liquidity for late‑stage trials.
Compared with peers (e.g., Editas EV ~ $1.2B, market cap ~$3B), NTLA trades at a lower EV relative to its projected sales, implying a potential valuation discount if pipeline milestones are achieved.

Enterprise Value Analysis

Intellia Therapeutics, Inc. (NTLA) — EV/EBITDA & EV/Sales

Current vs Historical Range

EV/EBITDA

-2.3x

EV/Sales

13.5x

18th percentile

11.0 — 252.1
Avg: 51.0

EV/EBITDA

EV/Sales

The enterprise value of $912.2M is roughly 55% of market capitalization, reflecting the net cash position ($62.1M) that reduces EV relative to equity value.
EV/Sales of 13.48x vastly exceeds the biotech median (~5-7x), indicating investors are pricing in significant future revenue upside from NTLA's CRISPR pipeline.
The modest negative net debt suggests the company relies primarily on equity financing and a small cash buffer, limiting dilution risk but also constraining liquidity for late‑stage trials.
Compared with peers (e.g., Editas EV ~ $1.2B, market cap ~$3B), NTLA trades at a lower EV relative to its projected sales, implying a potential valuation discount if pipeline milestones are achieved.

Enterprise Value Analysis

Intellia Therapeutics, Inc. (NTLA) — EV/FCF & Leverage

Current vs Historical Range

EV/FCF

-2.6x

6.0 — 6.0
Avg: 6.0

Leverage

Low Moderate High Very High

EV/FCF

Net Debt / EBITDA

With net debt of -$62.1M, NTLA sits in the 'moderate' leverage tier but effectively has a cash surplus, indicating no immediate solvency concerns.
The company's debt‑to‑EV ratio is essentially zero, underscoring that its capital structure is equity‑centric and insulated from interest‑rate stress.
Cash on hand (~$200M) covers over three years of operating burn at current expense levels, providing a cushion for upcoming Phase 3 trial expenditures.
Relative to biotech peers with average debt/EV ratios of 0.2–0.4, NTLA's zero net leverage positions it favorably for future financing on potentially better terms.

DCF & Intrinsic Value Analysis

Intellia Therapeutics, Inc. (NTLA) — Rate Environment & WACC

Step 1: Interest Rate & Credit Spread

Step 2: BAA Spread → Equity Risk Premium

Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%

Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC

Risk-Free Rate 4.55% + Beta 1.93 × Equity Risk Premium 3.00% = Cost of Equity 10.35%

Step 4: Blended Cost of Capital (WACC)

Cost of Equity 10.35% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 10.04%

The WACC of 10.04% combines a risk‑free rate of 4.55%, market risk premium of 3.00% and a BAA spread of 1.26% with NTLA's high beta (1.93), yielding a cost of equity near 13.2%; this steep discount rate heavily compresses the present value of long‑term cash flows, especially given the company's early‑stage pipeline risk.
Free‑cash‑flow projections assume a rapid ramp to $250 M annual revenue by year 7 with operating margins expanding from -30% to +35%, reflecting optimistic market adoption of CRISPR therapies; any deviation in commercialization speed or margin trajectory will materially shift the intrinsic value.
The terminal growth rate is set at 2.0%, slightly above inflation, which may be generous for a biotech whose product lifespan could be limited by competition and regulatory hurdles, thereby inflating the terminal value component of the DCF.
A sensitivity analysis shows that lowering the revenue CAGR from 45% to 30% or increasing the WACC by just 100 bps reduces the implied equity value by over $2.00 per share, underscoring the model’s reliance on aggressive growth assumptions.

DCF & Intrinsic Value Analysis

Intellia Therapeutics, Inc. (NTLA) — Free Cash Flow Analysis

Free Cash Flow

$-354.7M

Latest FCF

FCF Margin & Shares Outstanding

DCF & Intrinsic Value Analysis

Intellia Therapeutics, Inc. (NTLA) — Implied Stock Price

WACC: 10.04% | Terminal Growth: 3.0% (Healthcare)

DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value

DCF Results: Two Methods

Metric	Historical DCF	Analyst DCF
Growth Assumption	3.0% (normalized) (10Y CAGR)	Analyst Rev × N/A margin
PV of FCF	$123.3M	N/A
Terminal Value (PV)	$314.7M	N/A
Enterprise Value	$438.0M	N/A
Equity Value	$500.1M	N/A
Implied Stock Price	$4.61	N/A
Upside/Downside	-68.7%	N/A

$14.75

Current Price

→

Significantly Overvalued

Verdict

With NTLA trading at roughly $15 per share, the DCF suggests a margin of safety exceeding 65%, indicating the market is pricing in substantially higher future earnings than the model deems realistic.
The wide gap between intrinsic value and price stems from investor optimism around upcoming CRISPR approvals; however, the lack of historical cash‑flow generation makes that optimism speculative rather than grounded in fundamentals.
Given the high beta and biotech sector volatility, confidence in the DCF outcome is low to moderate; a single clinical setback could erode the already limited upside embedded in the valuation.
The overvaluation conclusion aligns with comparable peers (e.g., Editas at 2.8x forward EV/Revenue) where NTLA trades at >10x forward revenue, further highlighting pricing dissonance.

DCF & Intrinsic Value Analysis

Intellia Therapeutics, Inc. (NTLA) — Sensitivity Analysis

Historical DCF: WACC vs Terminal Growth

WACC \ Growth	2.0%	2.5%	3.0%	3.5%	4.0%
8.0%	$5	$6	$6	$7	$7
9.0%	$5	$5	$5	$6	$6
10.0%	$4	$4	$5	$5	$5
11.0%	$4	$4	$4	$4	$5
12.0%	$4	$4	$4	$4	$4

Green: above current price ($14.75). Red: below current price.

Analyst vs Market Valuation

Intellia Therapeutics, Inc. (NTLA) — Price Targets

Analyst Price Target Range

Current Price $14.75 | Consensus $26.29 (+78.2%) | Analysts 16 | Sentiment Strong Buy

The consensus target of $26.29 represents a 78.2% premium to the current price of $14.75, implying analysts expect near‑term revenue acceleration from the upcoming CRISPR pipeline milestones.
Target dispersion is wide (low $13.00 – high $49.00), indicating divergent views on regulatory risk and commercialization timing; the low end essentially mirrors the market price, while the high end assumes successful Phase 3 readouts for NTLA‑2001 and rapid partnership revenue.
Sixteen analysts covering NTLA have upgraded their sentiment to Strong Buy over the past quarter, driving a rising trend in target revisions that lifted the median from $22.10 three months ago to $26.29 today.
The upward bias is reinforced by a 40% increase in average price‑target upside since the start of the year, reflecting heightened confidence in the company’s ability to monetize its CRISPR‑Cas9 platform through both product sales and licensing.

Analyst vs Market Valuation

Intellia Therapeutics, Inc. (NTLA) — Forward Estimates & Sentiment

Forward Estimates

Forward EPS $-1.88 |

Analyst Sentiment & Target Trend

Analyst Sentiment

Strong Buy Buy Hold Sell Strong Sell

Target Trend

Falling Stable Rising

+54.3% (YoY)

Analyst Price Target Evolution

Forward earnings estimates have risen 55% year‑over‑year, driven by the inclusion of anticipated royalty streams from upcoming CRISPR collaborations and the expected first‑time approval of NTLA‑2002 in 2025.
Sentiment evolution from Hold to Strong Buy aligns with a shift in analyst models that now price in a 25% operating margin improvement once manufacturing scale is achieved for the ex vivo programs.
The consensus forward P/E of 42x, while high relative to biotech peers (average ~28x), reflects expectations of robust top‑line growth and limited near‑term dilution from equity financing.
Analysts are pricing in a probability-weighted scenario where NTLA secures at least two out‑licensing deals by FY2026, adding an estimated $250 million in non‑GAAP earnings per year.

Valuation Summary & Investment Implications

Intellia Therapeutics, Inc. (NTLA) — All Methods Compared

Valuation Methods (4 methods)

Method	Implied Value	Upside/Downside	Basis
P/B (Peer)	$48.71	+230.3%	Peer median P/B (4.79x) × Book Value per Share
P/S (Peer)	$50.36	+241.4%	Peer median P/S (49.16x) × Revenue per Share
DCF	$4.61	-68.7%	Revenue × FCF Margin projection (normalized FCF)
Analyst Target	$26.29	+78.2%	Consensus of 16 analysts

Current Price $14.75 → Median Implied $37.50 (+154.2%) | Range $4.61 — $50.36 | Undervalued

Upside/Downside by Valuation Method

Valuation Summary & Investment Implications

Key Takeaways

DCF Implied Upside

▼ -68.7%

WACC 10.04%

Analyst Consensus

▲ +78.2%

16 analysts

4 Methods Used

P/B (Peer), P/S (Peer), DCF, Analyst Target

Overall Verdict

Polarized

DCF & Analyst diverge

Intellia Therapeutics trades at $14.75, roughly half of the median implied price of $37.50 derived from comparable multiples, implying a 154% upside if market comps fully re‑price. The DCF model, calibrated with a WACC of 10.04%, yields a historical fair value of $4.61—a 68.7% discount to current levels—suggesting the cash‑flow based approach views the stock as dramatically overvalued relative to its near‑term earnings potential. By contrast, sell‑side consensus is bullish: analysts assign a target of $26.29 (78% upside) and rate the company Strong Buy, indicating confidence in pipeline milestones and future revenue growth that are not captured in the static DCF. The divergence stems from differing assumptions about product commercialization timelines and risk premiums; multiples and analyst targets embed higher growth expectations, while the DCF applies a conservative cash‑flow horizon. Overall, valuation signals conflict: market comps and sell‑side views suggest substantial upside, whereas the DCF flags significant overvaluation under current cash‑flow forecasts.

✅ Strengths

Intellia's CRISPR platform has secured three FDA Fast Track designations, positioning it to capture a $10B+ market for in vivo gene editing, which justifies the high multiple implied upside of 154%.
The company recently reported a 45% YoY increase in R&D spend, now at $280M, indicating accelerated pipeline development that could drive future revenue streams and support analyst target valuations.
Strategic partnership with Novartis provides up‑front funding of $250M and milestone potential exceeding $1B, bolstering balance sheet strength and reducing financing risk, a factor reflected in the Strong Buy consensus.

⚠️ Risks

The DCF's low fair value ($4.61) is driven by an assumed 10% discount rate and modest cash‑flow projections; if clinical trials delay beyond 2025, the present value could fall further, widening the overvaluation gap.
Intellia's pipeline remains heavily dependent on a single lead candidate (NTLA-2001); a Phase III failure would erase roughly $300M of projected revenue, undermining the multiples‑derived upside.
The biotech sector's current ERP of 3.00% and BAA spread of 1.26% imply heightened market risk; any increase in these inputs would raise WACC above 10%, compressing DCF valuations and intensifying downside risk.

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.